Murine models for antiretroviral therapy.

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• Rauscher murine leukemia virus (RLV) causes splenomegaly in infected mice, proportional to viral load.
• Chronic viremia and chemoprophylaxis require effective therapeutic strategies.
• Developing models to assess antiviral agents is crucial for treating retroviral infections.

Purpose of the Study:

• To evaluate antiviral therapies for Rauscher murine leukemia virus (RLV) infection in a murine model.
• To investigate the efficacy of single-agent and combination therapies for chronic viremia and chemoprophylaxis.
• To develop and utilize a murine neurotropic retrovirus model for assessing antiviral agents targeting the blood-brain barrier.

Main Methods:

• Utilized a Rauscher murine leukemia virus (RLV) infection model in adult mice.
• Administered single-agent and combination antiviral therapies.
• Developed a murine neurotropic retrovirus model for blood-brain barrier penetration studies.

Main Results:

• Prompt initiation of effective antiviral therapy post-viral exposure prevented de novo infection.
• The murine neurotropic retrovirus model enables analysis of antiviral agents crossing the blood-brain barrier.
• This model is applicable for studying therapeutic approaches in infections acquired during midgestation or neonatally.

Conclusions:

• Early antiviral intervention is effective in preventing Rauscher murine leukemia virus (RLV) infection.
• A novel murine neurotropic retrovirus model facilitates the evaluation of antivirals for central nervous system penetration.
• These models provide a platform for advancing retroviral therapeutic strategies.